APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biologics CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchBiologics CDMO Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics CDMO Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Biologics CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics CDMO Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics CDMO Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Biologics CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biologics CDMO include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologics CDMO market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics CDMO and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics CDMO sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologics CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics CDMO Segment by Company

AGC

Boehringer Ingelheim

Fujifilm Diosynth Biotechnologies

ICON Plc

Samsung Biologics

Toyobo

AbbVie

Lonza Group AG

Thermo Fisher Scientific

WuXi Biologics

Biologics CDMO Segment by Type

Biological Agent

Biosimilar Drug

Biologics CDMO Segment by Application

Cell Therapy

Drug Development

Others

Biologics CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics CDMO market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biologics CDMO Industry Trends Table 2. Biologics CDMO Industry Drivers Table 3. Biologics CDMO Industry Opportunities and Challenges Table 4. Biologics CDMO Industry Restraints Table 5. Global Biologics CDMO Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biologics CDMO Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biologics CDMO Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Biologics CDMO Sales Market Share by Manufacturers Table 9. Global Biologics CDMO Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Biologics CDMO Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biologics CDMO Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biologics CDMO Manufacturers, Product Type & Application Table 13. Global Biologics CDMO Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologics CDMO by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Biological Agent Table 17. Major Manufacturers of Biosimilar Drug Table 18. Global Biologics CDMO Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 20. Global Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 21. Global Biologics CDMO Sales Market Share by Type (2021-2026) Table 22. Global Biologics CDMO Sales Market Share by Type (2027-2032) Table 23. Global Biologics CDMO Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Biologics CDMO Revenue by Type (2021-2026) & (K Units) Table 25. Global Biologics CDMO Revenue by Type (2027-2032) & (K Units) Table 26. Global Biologics CDMO Revenue Market Share by Type (2021-2026) Table 27. Global Biologics CDMO Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Cell Therapy Table 29. Major Manufacturers of Drug Development Table 30. Major Manufacturers of Others Table 31. Global Biologics CDMO Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 33. Global Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 34. Global Biologics CDMO Sales Market Share by Application (2021-2026) Table 35. Global Biologics CDMO Sales Market Share by Application (2027-2032) Table 36. Global Biologics CDMO Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Biologics CDMO Revenue by Application (2021-2026) & (K Units) Table 38. Global Biologics CDMO Revenue by Application (2027-2032) & (K Units) Table 39. Global Biologics CDMO Revenue Market Share by Application (2021-2026) Table 40. Global Biologics CDMO Revenue Market Share by Application (2027-2032) Table 41. Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Biologics CDMO Sales by Region (2021-2026) & (K Units) Table 43. Global Biologics CDMO Sales Market Share by Region (2021-2026) Table 44. Global Biologics CDMO Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Biologics CDMO Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 48. North America Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 49. Europe Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 51. Europe Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 58. Global Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Biologics CDMO Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Biologics CDMO Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Biologics CDMO Revenue Market Share by Region (2021-2026) Table 62. Global Biologics CDMO Revenue Market Share by Region (2027-2032) Table 63. AGC Company Information Table 64. AGC Business Overview Table 65. AGC Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AGC Biologics CDMO Product Portfolio Table 67. AGC Recent Development Table 68. Boehringer Ingelheim Company Information Table 69. Boehringer Ingelheim Business Overview Table 70. Boehringer Ingelheim Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Boehringer Ingelheim Biologics CDMO Product Portfolio Table 72. Boehringer Ingelheim Recent Development Table 73. Fujifilm Diosynth Biotechnologies Company Information Table 74. Fujifilm Diosynth Biotechnologies Business Overview Table 75. Fujifilm Diosynth Biotechnologies Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio Table 77. Fujifilm Diosynth Biotechnologies Recent Development Table 78. ICON Plc Company Information Table 79. ICON Plc Business Overview Table 80. ICON Plc Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. ICON Plc Biologics CDMO Product Portfolio Table 82. ICON Plc Recent Development Table 83. Samsung Biologics Company Information Table 84. Samsung Biologics Business Overview Table 85. Samsung Biologics Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Samsung Biologics Biologics CDMO Product Portfolio Table 87. Samsung Biologics Recent Development Table 88. Toyobo Company Information Table 89. Toyobo Business Overview Table 90. Toyobo Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Toyobo Biologics CDMO Product Portfolio Table 92. Toyobo Recent Development Table 93. AbbVie Company Information Table 94. AbbVie Business Overview Table 95. AbbVie Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. AbbVie Biologics CDMO Product Portfolio Table 97. AbbVie Recent Development Table 98. Lonza Group AG Company Information Table 99. Lonza Group AG Business Overview Table 100. Lonza Group AG Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Lonza Group AG Biologics CDMO Product Portfolio Table 102. Lonza Group AG Recent Development Table 103. Thermo Fisher Scientific Company Information Table 104. Thermo Fisher Scientific Business Overview Table 105. Thermo Fisher Scientific Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Thermo Fisher Scientific Biologics CDMO Product Portfolio Table 107. Thermo Fisher Scientific Recent Development Table 108. WuXi Biologics Company Information Table 109. WuXi Biologics Business Overview Table 110. WuXi Biologics Biologics CDMO Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. WuXi Biologics Biologics CDMO Product Portfolio Table 112. WuXi Biologics Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Biologics CDMO Distributors List Table 116. Biologics CDMO Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Biologics CDMO Product Image Figure 2. Global Biologics CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics CDMO Sales (2021-2032) & (K Units) Figure 5. Global Biologics CDMO Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biologics CDMO Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Biological Agent Image Figure 9. Biosimilar Drug Image Figure 10. Global Biologics CDMO Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Biologics CDMO Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Biologics CDMO Sales Market Share by Type (2021-2032) Figure 13. Global Biologics CDMO Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Biologics CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Biologics CDMO Revenue Market Share by Type (2021-2032) Figure 16. Cell Therapy Image Figure 17. Drug Development Image Figure 18. Others Image Figure 19. Global Biologics CDMO Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Biologics CDMO Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Biologics CDMO Sales Market Share by Application (2021-2032) Figure 22. Global Biologics CDMO Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Biologics CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Biologics CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Biologics CDMO Sales Market Share by Country (2021-2032) Figure 27. U.S. Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Biologics CDMO Sales Market Share by Country (2021-2032) Figure 32. Germany Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Biologics CDMO Sales Market Share by Country (2021-2032) Figure 39. China Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Biologics CDMO Sales Market Share by Country (2021-2032) Figure 47. Brazil Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Biologics CDMO Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Biologics CDMO Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Biologics CDMO Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Biologics CDMO Revenue (2021-2032) & (US$ Million) Figure 58. North America Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Biologics CDMO Revenue (2021-2032) & (US$ Million) Figure 60. Europe Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Biologics CDMO Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Biologics CDMO Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Biologics CDMO Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Biologics CDMO Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Biological Agent
  • Biosimilar Drug
Applications
  • Cell Therapy
  • Drug Development
  • Others
Companies covered
  • AGC
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies
  • ICON Plc
  • Samsung Biologics
  • Toyobo
  • AbbVie
  • Lonza Group AG
  • Thermo Fisher Scientific
  • WuXi Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologics CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologics CDMO Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biologics CDMO Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biologics CDMO Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biologics CDMO Market Dynamics
  1. 2.1 Biologics CDMO Industry Trends
  2. 2.2 Biologics CDMO Industry Drivers
  3. 2.3 Biologics CDMO Industry Opportunities and Challenges
  4. 2.4 Biologics CDMO Industry Restraints
3 Biologics CDMO Market by Manufacturers
  1. 3.1 Global Biologics CDMO Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biologics CDMO Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biologics CDMO Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biologics CDMO Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologics CDMO Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biologics CDMO Manufacturers, Product Type & Application
  7. 3.7 Global Biologics CDMO Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologics CDMO Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologics CDMO Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologics CDMO Tier 1, Tier 2, and Tier 3
4 Biologics CDMO Market by Type
  1. 4.1 Biologics CDMO Type Introduction
  2. 4.1.1 Biological Agent
  3. 4.1.2 Biosimilar Drug
  4. 4.2 Global Biologics CDMO Sales by Type
  5. 4.2.1 Global Biologics CDMO Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Biologics CDMO Sales by Type (2021-2032)
  7. 4.2.3 Global Biologics CDMO Sales Market Share by Type (2021-2032)
  8. 4.3 Global Biologics CDMO Revenue by Type
  9. 4.3.1 Global Biologics CDMO Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Biologics CDMO Revenue by Type (2021-2032)
  11. 4.3.3 Global Biologics CDMO Revenue Market Share by Type (2021-2032)
5 Biologics CDMO Market by Application
  1. 5.1 Biologics CDMO Application Introduction
  2. 5.1.1 Cell Therapy
  3. 5.1.2 Drug Development
  4. 5.1.3 Others
  5. 5.2 Global Biologics CDMO Sales by Application
  6. 5.2.1 Global Biologics CDMO Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics CDMO Sales by Application (2021-2032)
  8. 5.2.3 Global Biologics CDMO Sales Market Share by Application (2021-2032)
  9. 5.3 Global Biologics CDMO Revenue by Application
  10. 5.3.1 Global Biologics CDMO Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biologics CDMO Revenue by Application (2021-2032)
  12. 5.3.3 Global Biologics CDMO Revenue Market Share by Application (2021-2032)
6 Global Biologics CDMO Sales by Region
  1. 6.1 Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics CDMO Sales by Region (2021-2032)
  3. 6.2.1 Global Biologics CDMO Sales by Region (2021-2026)
  4. 6.2.2 Global Biologics CDMO Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biologics CDMO Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biologics CDMO Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biologics CDMO Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biologics CDMO Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biologics CDMO Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biologics CDMO Revenue by Region
  1. 7.1 Global Biologics CDMO Revenue by Region
  2. 7.1.1 Global Biologics CDMO Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biologics CDMO Revenue by Region (2021-2026)
  4. 7.1.3 Global Biologics CDMO Revenue by Region (2027-2032)
  5. 7.1.4 Global Biologics CDMO Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biologics CDMO Revenue (2021-2032)
  8. 7.2.2 North America Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biologics CDMO Revenue (2021-2032)
  11. 7.3.2 Europe Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biologics CDMO Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biologics CDMO Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biologics CDMO Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AGC
  2. 8.1.1 AGC Company Information
  3. 8.1.2 AGC Business Overview
  4. 8.1.3 AGC Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AGC Biologics CDMO Product Portfolio
  6. 8.1.5 AGC Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Fujifilm Diosynth Biotechnologies
  14. 8.3.1 Fujifilm Diosynth Biotechnologies Company Information
  15. 8.3.2 Fujifilm Diosynth Biotechnologies Business Overview
  16. 8.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
  18. 8.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
  19. 8.4 ICON Plc
  20. 8.4.1 ICON Plc Company Information
  21. 8.4.2 ICON Plc Business Overview
  22. 8.4.3 ICON Plc Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ICON Plc Biologics CDMO Product Portfolio
  24. 8.4.5 ICON Plc Recent Developments
  25. 8.5 Samsung Biologics
  26. 8.5.1 Samsung Biologics Company Information
  27. 8.5.2 Samsung Biologics Business Overview
  28. 8.5.3 Samsung Biologics Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Samsung Biologics Biologics CDMO Product Portfolio
  30. 8.5.5 Samsung Biologics Recent Developments
  31. 8.6 Toyobo
  32. 8.6.1 Toyobo Company Information
  33. 8.6.2 Toyobo Business Overview
  34. 8.6.3 Toyobo Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Toyobo Biologics CDMO Product Portfolio
  36. 8.6.5 Toyobo Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Biologics CDMO Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Lonza Group AG
  44. 8.8.1 Lonza Group AG Company Information
  45. 8.8.2 Lonza Group AG Business Overview
  46. 8.8.3 Lonza Group AG Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lonza Group AG Biologics CDMO Product Portfolio
  48. 8.8.5 Lonza Group AG Recent Developments
  49. 8.9 Thermo Fisher Scientific
  50. 8.9.1 Thermo Fisher Scientific Company Information
  51. 8.9.2 Thermo Fisher Scientific Business Overview
  52. 8.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
  54. 8.9.5 Thermo Fisher Scientific Recent Developments
  55. 8.10 WuXi Biologics
  56. 8.10.1 WuXi Biologics Company Information
  57. 8.10.2 WuXi Biologics Business Overview
  58. 8.10.3 WuXi Biologics Biologics CDMO Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 WuXi Biologics Biologics CDMO Product Portfolio
  60. 8.10.5 WuXi Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologics CDMO Value Chain Analysis
  2. 9.1.1 Biologics CDMO Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologics CDMO Production Mode & Process
  6. 9.2 Biologics CDMO Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologics CDMO Distributors
  9. 9.2.3 Biologics CDMO Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst